AMATSIGROUP Acquires SEPS Pharma In Belgium, To Continue Its International Expansion And Strengthen Its Formulation Expertise

• AmatsiGroup intensifies its development and formulation of pharmaceutical products

• Amplification of AmatsiGroup’s formulation development activities

• Further international expansion following its establishment in the United


Toulouse (France), January 26, 2015 – AMATSIGROUP, the leading French supplier of services devoted to the development of both human and veterinary pharmaceutical products, announces the acquisition of Belgian company SEPS Pharma, which provides drug product development services, encompassing preformulation and formulation development, analytical drug product development, process development and clinical trial manufacturing.

Founded in 2007 and located in Ghent, Belgium, SEPS Pharma counts a team of 30 highly-qualified people specialized in the development of innovative oral (liquid and solid dosage forms), inhalable and injectable formulations with acknowledged expertise in enhancing the bioavailability and controlling the drug release. With over 25 clients in Europe, US and Japan, the Belgian company recorded a 2014 revenue of €5 million.

Within the framework of its international development and the expansion of its service offer aimed at the Pharmaceutical industry, AMATSIGROUP will thus extend its services relating to the development of drugs for its clients, biotechs, Mid-size or Big Pharmas, to SEPS Pharma’s Belgian site. Thanks to this acquisition, AmatsiGroup intends to continue its growth and is targeting annual revenue of €33 million in 2015, versus €26 million in 2014 and €23 million in 2013. Alain Sainsot, CEO of AMATSIGROUP, says:

“This acquisition further strengthens our positioning in the upstream phases that are the formulation and perfecting of analytical methods and processes in addition to our preclinical and clinical batch manufacturing and logistics activities. Thanks to the integration of SEPS Pharma, we are intensifying our international development just a few months after we established a presence in the United States. By establishing ourselves in Belgium, we are increasing our proximity with Northern Europe’s major pharmaceutical laboratories.”

Yves Gonnissen, CEO of SEPS Pharma, adds:

“We are extremely proud of everything the SEPS Pharma team has accomplished so far. Our acknowledged expertise in the development of innovative formulations represents substantial potential synergies with AMATSIGROUP’s activities, and we consider the latter to be the ideal partner to successfully undertake the international development of our service offer aimed at pharmaceutical laboratories.”

Please find attached the press release

About AMATSIGROUP

AMATSIGROUP, as a CDMO (Contract Development and Manufacturing Organisation), provides services throughout both preclinical and clinical phases in veterinary and human drugs. AMATSIGROUP, founded in 2010, was formed by the integration of four companies (Avogadro, Amatsi, DBI and Avepharm) bringing complementary expertise. With the reinforcement of more than 200 highly-qualified staff and a diversified portfolio of 300 clients, AMATSIGROUP is the leading French company in its sector. AMATSIGROUP generated annual revenue of €26 million in 2014 and contributes to the development and registration of more than 30 pharmaceutical products for its clients every year. The Group operates from facilities based in the South of France and now in the USA.

CONTACTS :
NewCap
Media Relations
Nicolas Merigeau
Tel : 00 33 (0)1 44 71 94 98
nmerigeau@newcap.fr

Help employers find you! Check out all the jobs and post your resume.

Back to news